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COMPARISON OF OUTCOMES AFTER TRANSPLANTATION OF UNRE-
LATED DONOR UMBILICAL CORD BLOOD VERSUS MATCHED SIBLING
BONE MARROW FOR PEDIATRIC PATIENTS WITH LEUKEMIA AND
MYELODYSPLASTIC SYNDROMES
Rodriguez-Marino, S.1, Rademaker, A.2, Kletzel, M.1, Duerst, R.1 1.
Children’s Memorial Hospital, Chicago, IL; 2. Department of Preventive
Medicine, Northwestern University, Chicago, IL
Are unrelated Umbilical Cord Blood (U-UCB) source of stem
cells equivalent to matched sibling bone marrow (MS-BM) for
treatment of pediatric patients with leukemia and myelodysplastic
syndromes (MDS)? To address this question, we retrospectively
studied the outcomes of 110 children that received a Hematopoi-
etic Stem Cell Transplant (HSCT) at Children’s Memorial Hos-
pital between 1992 and 2003 for treatment of leukemia or MDS.
Patients underwent a uniform conditioning regimen and similar
graft-vs.-host disease (GVHD) prophylaxis followed by HSCT
with either U-UCB or MS-BM. Patients receiving other regimens
or stem cell sources were excluded from this analysis. The condi-
tioning regimen was comprised of fractionated total body irradia-
tion (fTBI, 150 cGy  8  1200 cGy), etoposide (1000 mg/m2)
and cyclophosphamide (60 mg/kg/d 3d) for both stem cell
sources. GVHD prophylaxis was comprised of CsA (3 mg/kg/d),
methotrexate (15 mg/m2 day 1 and 10 mg/m2 days 3 and 6)
and (for UCB recipients) equine ATG (20 mg/kg days 1, 3, 5
and 7).
These results for HSCT in pediatric leukemia and MDS
patients suggest that relapse free survival and overall survival are
similar between these two groups and the only difference is time
to engraftment (slower in U-UCB). Thus, pediatric leukemia
patients previously considered HSCT candidates only if
MS-BM was available should be considered candidates for
HSCT if an U-UCB unit of adequate size can be identiﬁed.
16
ALLOGENEIC HSCT WITH REDUCED INTENSITY CONDITIONING REGI-
MENS IN HIGH RISK PATIENTS WITH MYELOFIBROSIS
Rondelli, D.1,7, Barosi, G.2,7, Bacigalupo, A.3,7, Prchal, J.T.4,7, Popat,
U.4,7, Alessandrino, E.P.2,7, Spivak, J.L.5,7, Hoffman, R.1,7, Frucht-
man, S.6,7 1. University of Illinois at Chicago, Chicago, IL; 2. IRCCS
Policlinico San Matteo, Pavia, Pavia, Italy; 3. Ospedale San Martino,
Genova, Genova, Italy; 4. Baylor College of Medicine, Houston, TX; 5.
Johns Hopkins University, Baltimore, MD; 6. Mount Sinai School of
Medicine, New York, NY; 7. MPD Research Consortium
Idiopathic Myeloﬁbrosis (IM) is a rare chronic myeloproliferative
disorder without curative treatment. The main therapeutic option
remains transfusion support. For patients with high risk Lille
scores (Hb  10g; WBC 4,000 or 30,000) the median survival
is less than 2 years. Fully ablative allogeneic conditioning results in
a 25% peritransplant mortality, with few long term DFS in this
typically elderly group. We report on 20 patients, median age 54
yrs (range:27-68), who received a non-myeloablative allogeneic
HSC transplantation from HLA-matched related (n  18) or
unrelated (n  1), or 1Ag-mismatched related donor (n  1).
Marked splenomegaly was present in 15 pts, in the remaining 5, 3
were splenectomized. Eighteen of 20 pts had grade III/IV marrow
ﬁbrosis and 9 pts were RBC and 3 PLT transfusion-dependent.
Reduced intensity conditioning (RIC) regimens included low doses
TBI (200 cGy) and Fludara (n  5), Fludara/Melphalan (n  6),
Thiotepa/EDX (n  8) and Thiotepa/Fludara (n  1). Engraft-
ment of ANC500 and Plt20K occurred within days 12-18 and
16-77, respectively, in all pts. Chimerism analysis on d30 showed
90% donor cells in 18/20, while the remaining 2 (70% and 56%)
achieved 100% after DLI. Acute GVHD grade II-IV was observed
in 5 patients and chronic GVHD in 8 of 16 evaluable pts. Day 100
TRM was 0%. Eighteen of 20 pts (90%) are alive at 18 months
median follow-up. Two deaths were due to aGVHD and
aGVHD  aspergillosis (post DLI). Marrow ﬁbrosis was reduced
to grade 1 in the majority of the patients. CBC also improved after
transplant since median values of Hb and Plt pre- and post-Tx are:
8.1 g/dL (range: 6.2-10.7) vs 10.0 g/dL (range: 8.1-15.5), and 70 
109/L (range: 8-278) vs 110  109/L (range: 17-340), respectively.
Splenomegaly was dramatically reduced in all patients. Allogeneic
HSC transplantation with RIC regimens can be safely performed
in IM patients, with 1) low TRM 2) eradication of marrow ﬁbrosis
and massive organomegaly and 3) restoration of more normal
hematopoiesis. These provocative outcomes will prompt random-
ized trials in IM, including allogeneic transplantation for patients
with a matched donor.
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EFFECT OF COMORBIDITIES ON ALLOGENEIC HEMATOPOIETIC STEM
CELL TRANSPLANT OUTCOMES IN AML/MDS PATIENTS IN FIRST COM-
PLETE REMISSION
Shahjahan, M., Alamo, J., de Lima, M., Khouri, I., Gajewski, J.,
Andersson, B., Champlin, R., Giralt, S.M University of Texas MD
Anderson Cancer Center, Houston, TX
Introduction: Comorbidities can have signiﬁcant impact on
both survival and treatment selection in several types of malignan-
cies. However, little attention has been paid in the literature to
assess the effect of comorbidity on transplant outcomes in hema-
tologic malignancies. We studied the impact of comorbidities on
outcomes of allogeneic hematopoietic stem cell transplant (HSCT)
in acute myeloid leukemia (AML) and myelodysplastic syndrome
(MDS) patients in 1st complete remission (CR). Methods:
Seventy-eight patients with AML or MDS who received a matched
or partially mismatched bone marrow, peripheral blood or cord
blood transplant from a related or unrelated donor between Janu-
ary 1990 and December 2001 at the University of Texas MD
Anderson Cancer Center were retrospectively reviewed. Data on
demographics, comorbid conditions, and transplant outcomes were
collected from the Blood and Marrow Transplantation database,
patient charts and institutional electronic clinical information re-
trieval system. Charlson Comorbidity Index (CCI) was used to
score comorbid conditions and CCI score was calculated for each
Table.
Stem Cell Source
Matched Sibling
BM Unrelated UCB P Value
Male/female
(number,
percent) 34 (64%), 19 (36%) 31 (54%), 26 (46%) 0.34
Age at
HSCT(years),
(median, range) 9.2 (0.5, 23.0) 7.1 (0.7-20.7) 0.47
ALL, AML, other
35 (66%), 14 (26%),
4 (8%)
23 (40%), 17 (30%),
17 (30%) 0.004
Caucasian, Hispanic,
African
American, Asian
(number,
percent)
34 (65%), 11 (21%),
3 (6%), 4 (8%)
25 (44%), 14 (25%),
13 (23%), 5 (9%) 0.04
15, 30, 45, 60 day
ANC
Engraftment
42%, 79%, 86%,
92% 4%, 48%, 91%, 95% 0.001
15, 30, 45, 60 day
Platelet
Engraftment
13%, 60%, 77%,
85% 2%, 20%, 44%, 64% 0.007
100 Days Survival
(number,
percent) 43 (81%) 44 (77%) 0.65
Chronic GVHD
(number,
percent) 4/41 (10%) 8/44 (18%) 0.35
Relapse (number,
percent) 12 (23%) 8 (14%) 0.32
1, 2, 3 Year Relapse-
free Survival 63%, 57%, 54% 61%, 53%, 53% 0.97
1, 2, 3 Year Overall
Survival 65%, 58%, 58% 57%, 50%, 50% 0.56
Oral Presentations
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